Previous close | 3.4100 |
Open | 3.3900 |
Bid | 3.1100 x 800 |
Ask | 3.5000 x 900 |
Day's range | 3.3400 - 3.4350 |
52-week range | 1.6200 - 4.1390 |
Volume | |
Avg. volume | 120,149 |
Market cap | 236.78M |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6800 |
Earnings date | 03 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.00 |
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizures NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines des
Ovid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call